From all of us at Verbatim Pharma, Happy 4th of July to all of our valued clients and candidates across the globe! 🎆 Wishing you all a fantastic Independence Day filled with memorable celebrations 🎊 #4thJuly #IndependenceDay #USA #VerbatimPharma
Verbatim Pharma’s Post
More Relevant Posts
-
Top 10 Pharma Companies South Africa Ranking The following chart shows the top 10 corporation in the South African pharma market. Domestic champions #Aspen and #Adcock Ingram lead the way in terms of market share and most of the top 10 are growing well above the market average.
To view or add a comment, sign in
-
-
Senior Analyst @ The Smart Cube | Metvy x IIMB | XLRI Product Management | LBSIM | Procurement | Market Analysis, Primary and Secondary Research
Ozempic and Wegovy have propelled Novo Nordisk to Europe's second-most valuable company, but the drugmaker is trying to come to grips with its newfound fame. The company's struggles to meet demand are raising questions about whether it can stay on top of the wave that's boosted its market capitalization to $423 billion • Novo's supply glitches, including problems at a contractor, have left it unable to fully capitalize on its first-mover advantage before rival Eli Lilly & Co's Mounjaro hits the weight-loss market. CEO Lars Fruergaard Jorgensen concedes the company miscalculated the frenzy its obesity drugs would spark. The success of Ozempic and Wegovy has also created something of a gold rush in the pharma industry, with about 40 companies -- including heavyweights Pfizer and Amgen- developing products that willintensify competition. All of that means Novo, which trades at a multiple almost double that of its peers, has little room for error. #lifesciences #MedicalBreakthrough #pharmamarketing #novo
To view or add a comment, sign in
-
-
• Ozempic and Wegovy have propelled Novo Nordisk to Europe's second-most valuable company, but the drugmaker is trying to come to grips with its newfound fame. The company's struggles to meet demand are raising questions about whether it can stay on top of the wave that's boosted its market capitalization to $423 billion. • Novo's supply glitches, including problems at a contractor, have left it unable to fully capitalize on its first-mover advantage before rival Eli Lilly & Co.'s Mounjaro hits the weight-loss market. CEO Lars Fruergaard Jorgensen concedes the company miscalculated the frenzy its obesity drugs would spark. • The success of Ozempic and Wegovy has also created something of a gold rush in the pharma industry, with about 40 companies - including heavyweights Pfizer and Amgen - developing products that will intensify competition. All of that means Novo, which trades at a multiple almost double that of its peers, has little room for error.
To view or add a comment, sign in
-
-
During the ‘Ease of Doing Business’ panel at the #OPPIAnnualSummit 2023, the esteemed panelists discussed the current challenges facing pharma companies & the measures needed to ensure ease-of-doing business, as the country moves towards India@100. #BharatKeLiye
To view or add a comment, sign in
-
-
#PRESS: CEO COMMENT ON NOMINATION TO BECOME NEXT CHAIRMAN - “Given the path lying ahead of PILA PHARMA, I have recently evaluated that I will best serve the Shareholders of PILA PHARMA by becoming the Company’s next Chairman of the Board. At the General Meeting on 18 April 2024, I hope to get the shareholders support for this move and the underlying plan of recalibrating PILA PHARMA for future success. Should I get the support from our shareholders and become the next Chairman of the Board in PILA PHARMA, I will immediately step down as CEO and the company will work to find a new CEO who can secure the company’s future success. Some have told me that I’m the identity of PILA PHARMA and I believe that’s true. But for me PILA PHARMA is also my identity! So, there should be no doubt that I will keep working relentlessly for our Company’s success – and from April hopefully as working Chairman in a strong partnership with a new CEO.“ https://lnkd.in/e7GtXndZ
To view or add a comment, sign in
-
-
"Celebrating Independence with Style and Confidence! 🇮🇳✨ Gennext Pharma™️ is not just about medicines, but also about embracing the spirit of freedom and self-expression. Our Independence Day decorations reflect the beauty of individuality and the journey towards self-confidence. Let your inner spirit shine as bright as the tricolor! #IndependenceDay #GennextPharma #HealthAndFreedom #ProudToBeIndian #MedicineAndCare #ConfidenceBoost #CelebrateWithUs #IndependenceDayDecor #TransformingLives #SelfExpression #TricolorVibes"
To view or add a comment, sign in
-
-
How they say don’t let a doubt sit in you, rather sit in the doubt and find the answer. We make it easier even for you, just raise your hand and our experts will answer your questions. After the 3-day conference our experts Kartik S, Jayesh Khatri, and AMIT SHARMA, clarifies all doubts of delegates with our Managing Director & Moderator of the panel discussion Guneet Kaur Hayer at the 7th Annual Pharma Project and Portfolio Management 2024. #eminencebusinessmedia #ebmpppm7 #pharmaproject #pharmaportfolio #eminencegroupventures Dr. Reddy's Laboratories , Fresenius Kabi , Ashish Life Science
To view or add a comment, sign in
-
-
I'm looking forward to moderating a panel discussion at BioAsia 2024, taking place from February 26-28 in Hyderabad. Our discussion will focus on the evolution of Global Capability Centres (GCCs) and their increasing importance in transforming their parent organizations. We'll explore how GCCs can harness new technologies to foster innovation and drive change. #BioAsia2024 #LifeSciences #DataAndAI #GlobalCapabilityCentres #Innovation
Here's another panel discussion that will get you excited! Our experts will speak about the potential of GCCS in this power-packed session on 28th Feb. BioAsia 2024 is definitely the place to be! Book now! 26-28 February | HICC, Hyderabad @Siva Kumar Padmanabhan AstraZeneca Madhav Vattikuti CALYX Mrinal Duggal Sanofi Vani Kodandaram Bristol Myers Squibb Sanjay Vyas Parexel Sunil Venkatesh EY Shakthi M Nagappan Telangana Lifesciences #BioAsia2024 #TelanganaLeadsLifesciences #RedefiningPossibilities #21YearsofBioAsia
To view or add a comment, sign in
-
-
MARKET TRENDS: According to GlobalData Plc, 32 pharma deals (Strategic alliances- excluding deals for co-development) for #NMEs took place in India. Interestingly, six of those deals are involved in co-marketing. https://lnkd.in/gHFPa2WU #pharma #biopharma #deals #marketing #alliances #comarketing #researchanddevelopment #biovoicenews
To view or add a comment, sign in
-
💊 Step into a new era of healthcare transformation at the #ETREPharmaSummit! Join us for the Inaugural Session, where we unravel the paradigm shift from 'volume to value in the Indian Pharmaceutical Ecosystem'. Key Takeaways- Vikrant Shrotriya - Corporate Vice President & Managing Director, Novo Nordisk India Private Limited "Innovation is the centerpiece in taking forward healthcare." "Animal trials are not needed in many of the settings today." Sukanya Choudhury - Executive Vice President – Regulatory Affairs, GSK Pharmaceuticals "We have the will to Make in India to Discover in India" "The use of AI in drug development is used widely. We need to have more conversations on how to leverage AI in manufacturing" Jitendra Kumar, Managing Director, BIRAC "The nitty-gritty of schemes is not laid out properly which can be frustrating." "Even if all the nitty-gritty is taken care of there is not enough participation" bhalchandra Barve, Joint Managing Director, Blue Cross Laboratories Ltd. "All of us have to gear up so that the schemes reach the right people who can take advantage of it." "We are requesting the government to reinstate the R&D incentives." kaushik desai, Secretary General, IPEC (Moderator) Know More: https://bit.ly/41bwcoa #PharmaInnovation #HealthcareReform #Summit #Healthcare #IndustryLeaders #PharmaSolutions #FutureOfPharma #LiveSession
To view or add a comment, sign in
-